Properties of cardioinhibitory factors produced in shock.
The widespread occurrence of circulating cardioinhibitory factors in many types of circulatory shock and in a variety of mammalian species is impressive. This review summarizes the properties of the nine best-known factors with regard to their occurrence, chemical properties, sites of origin, biological actions, and pharmacological modification. Cardioinhibitory factors appear to play a significant role in the pathogenesis of circulatory shock. There now are pharmacological means available with which to prevent the formation of such factors. With knowledge on the chemistry of cardioinhibitory factors rapidly accumulating, it is anticipated that specific antagonists to the action of these factors will become available in the near future.
D000818:Animals; D001681:Biological Assay; D003864:Depression, Chemical; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008638:Mesenteric Arteries; D008970:Molecular Weight; D012157:Mononuclear Phagocyte System / Q000503:physiopathology; D009200:Myocardial Contraction; D010455:Peptides / Q000097:blood; D011453:Prostaglandins / Q000627:therapeutic use; D012769:Shock / Q000097:blood / Q000503:physiopathology* / Q000628:therapy; D014661:Vasoconstriction / Q000187:drug effects
D005938:Glucocorticoids; D010455:Peptides; D011453:Prostaglandins